ARTICLE | Company News
Arrowhead prunes pipeline over toxicity concerns
November 30, 2016 12:35 AM UTC
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) sank $2.63 (60%) to $1.76 in early after-hours trading after it said will discontinue development of all programs using its EX1 liver-targeted, IV delivery vehicle for its RNA therapies. The cuts include HBV candidates ARC-520 and ARC-521, as well as alpha-antitrypsin deficiency (AATD) candidate ARC-AAT.
Earlier this month, FDA placed a clinical hold on the Phase IIb Heparc-2004 trial of ARC-520 to treat HBV after deaths occurred in a non-human primate toxicology study that included high doses of EX1. On Tuesday, Arrowhead said that resolving the hold would involve "substantial delays" (see BioCentury Extra, Nov. 9)...
BCIQ Company Profiles